Our top pick for
uniQure N.V is a biotechnology business based in the US. uniQure N-V shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. uniQure N-V employs 248 staff and has a trailing 12-month revenue of around USD$5.3 million.
|Latest market close||USD$39.86|
|52-week range||USD$34.38 - USD$76.6869|
|50-day moving average||USD$38.2766|
|200-day moving average||USD$48.7476|
|Wall St. target price||USD$74|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.795|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-2.73%|
|1 month (2020-12-15)||-16.72%|
|3 months (2020-10-15)||12.00%|
|6 months (2020-07-15)||-11.22%|
|1 year (2020-01-15)||-42.70%|
|2 years (2019-01-15)||25.70%|
|3 years (2018-01-12)||126.61%|
|5 years (2016-01-15)||150.69%|
|Revenue TTM||USD$5.3 million|
|Gross profit TTM||USD$-87,456,000|
|Return on assets TTM||-26.82%|
|Return on equity TTM||-68.21%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
There are currently 4.0 million uniQure N-V shares held short by investors – that's known as uniQure N-V's "short interest". This figure is 8.7% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting uniQure N-V shares can be evaluated.
uniQure N-V's "short interest ratio" (SIR) is the quantity of uniQure N-V shares currently shorted divided by the average quantity of uniQure N-V shares traded daily (recently around 445170.52280311). uniQure N-V's SIR currently stands at 8.99. In other words for every 100,000 uniQure N-V shares traded daily on the market, roughly 8990 shares are currently held short.
However uniQure N-V's short interest can also be evaluated against the total number of uniQure N-V shares, or, against the total number of tradable uniQure N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case uniQure N-V's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 uniQure N-V shares in existence, roughly 90 shares are currently held short) or 0.1007% of the tradable shares (for every 100,000 tradable uniQure N-V shares, roughly 101 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against uniQure N-V.
Find out more about how you can short uniQure N-V stock.
We're not expecting uniQure N-V to pay a dividend over the next 12 months.
Over the last 12 months, uniQure N-V's shares have ranged in value from as little as $34.38 up to $76.6869. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while uniQure N-V's is 1.1208. This would suggest that uniQure N-V's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.